Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $125.85
    -1.72 (-1.35%)

    Market Cap: $10.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kymera Therapeutics Inc (KYMR) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Kymera Therapeutics reported revenue of $39.21M for the fiscal year ended Dec 31, 2025, down 16.7% from the year before. That year, net income was -$311.35M with a net margin of -794.0%, operating cash flow was -$232.89M and free cash flow was -$234.34M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$132.00M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $2.93M, a compound annual rate of 54.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$39.21M-16.7%100.0%-891.1%-794.0%
    Dec 2024$47.07M-40.1%100.0%-555.8%-475.6%
    Dec 2023$78.59M+67.8%100.0%-210.6%-187.0%
    Dec 2022$46.83M-35.7%100.0%-344.4%-330.6%
    Dec 2021$72.83M+114.0%100.0%-138.0%-137.6%
    Dec 2020$34.03M+1060.0%100.0%-136.1%-134.0%
    Dec 2019$2.93MN/A100.0%-1438.5%-1405.8%
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$39.21M$47.07M$78.59M$46.83M$72.83M$34.03M$2.93M$0
    Cost of revenue$0$0$0$0$0$0$0$205.00K
    Gross profit$39.21M$47.07M$78.59M$46.83M$72.83M$34.03M$2.93M-$205.00K
    Research and development$316.57M$240.25M$189.08M$164.25M$137.02M$62.10M$37.16M$17.68M
    Operating income-$349.40M-$261.63M-$165.53M-$161.26M-$100.53M-$46.30M-$42.20M-$21.45M
    Net income-$311.35M-$223.86M-$146.96M-$154.81M-$100.22M-$45.59M-$41.25M-$21.47M
    EBITDA-$303.04M-$216.49M-$143.40M-$151.83M-$97.82M-$43.83M-$40.42M-$21.25M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M$3.74M$25.65M$10.29M$47.88M
    Gross profit$0$65.00M$34.37M$2.87M$2.76M$11.48M$22.10M$7.39M$3.74M$25.65M$10.29M$47.88M
    Operating income-$147.23M-$75.61M-$84.15M-$97.89M-$92.52M-$84.56M-$74.43M-$80.75M-$72.12M-$50.92M-$57.83M-$19.31M
    Net income-$132.00M-$61.21M-$69.23M-$86.98M-$82.17M-$76.61M-$65.58M-$70.75M-$62.49M-$42.06M-$48.56M-$14.37M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $13.76M by $343.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$1.74B$978.03M$575.76M$603.13M$605.90M$487.18M$116.70M$44.23M
    Current assets$871.21M$510.27M$405.32M$419.42M$451.27M$302.34M$92.84M$41.79M
    Cash and equivalents$357.01M$120.26M$109.97M$68.39M$47.98M$31.00M$76.02M$41.26M
    Total liabilities$163.15M$142.42M$180.79M$112.98M$146.27M$203.29M$82.03M$78.67M
    Short-term debt$13.76M$13.11M$6.34M$3.94M$3.60M$3.26M$3.38M$302.00K
    Shareholder equity$1.58B$835.62M$394.97M$490.15M$459.64M$283.89M-$74.41M-$34.44M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.77B$1.65B$1.67B$1.74B$1.10B$1.13B$918.31M$978.03M$1.03B$826.02M$868.25M$575.76M
    Total liabilities$152.74M$136.19M$129.38M$163.15M$155.79M$159.59M$132.08M$142.42M$141.91M$141.10M$157.05M$180.79M
    Cash and equivalents$373.37M$124.48M$144.09M$357.01M$112.95M$335.82M$89.97M$120.26M$110.72M$67.61M$93.51M$109.97M
    Shareholder equity$1.61B$1.51B$1.54B$1.58B$946.26M$971.48M$786.23M$835.62M$892.93M$684.92M$711.20M$394.97M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$232.89M-$194.50M-$102.83M-$153.09M-$128.95M$88.13M$17.91M-$17.86M
    Capital expenditures$1.45M$12.84M$34.48M$2.84M$1.60M$9.10M$532.00K$1.36M
    Free cash flow-$234.34M-$207.34M-$137.31M-$155.92M-$130.54M$79.03M$17.37M-$19.22M
    Investing cash flow-$521.06M-$404.08M$139.89M$20.52M-$99.83M-$422.59M-$16.49M-$1.36M
    Financing cash flow$990.71M$608.85M$4.19M$153.00M$250.28M$289.26M$34.91M$52.93M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$77.91M-$54.06M-$88.84M-$66.75M-$27.11M-$59.88M-$79.15M-$61.78M-$50.19M-$42.94M-$39.59M$8.04M
    Capital expenditures$315.00K$473.00K$434.00K$106.00K$181.00K$695.00K$467.00K$936.00K$189.00K$4.69M$7.40M$11.63M
    Free cash flow-$78.23M-$54.54M-$89.27M-$66.85M-$27.29M-$60.58M-$79.62M-$62.72M-$50.38M-$47.63M-$46.99M-$3.58M
    Last 12 quarters

    Frequently Asked Questions About KYMR

    What is Kymera Therapeutics' annual revenue?

    Kymera Therapeutics reported revenue of $39.21M for the fiscal year ended Dec 31, 2025.

    How fast is Kymera Therapeutics' revenue growing?

    Revenue was down 16.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.7%.

    Is Kymera Therapeutics profitable?

    No. Kymera Therapeutics reported net income of -$311.35M for the fiscal year ended Dec 31, 2025, with a net margin of -794.0%.

    How much free cash flow does KYMR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$232.89M minus capital expenditures of $1.45M produced free cash flow of -$234.34M.

    How much debt does Kymera Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $13.76M and cash and equivalents of $357.01M.